ClinicalTrials.gg
CompletedNCT05015530ISONAMUpdated Nov 8, 2024Results posted

Impact of Symbiofilm On Nasal Microbiota

An observational study in Rhinosinusitis Chronic and Microbiome, sponsored by Lallemand Pharma AG. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Lallemand Pharma AG · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
12
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Rhinosinusitis with a site in France — 4 open to participants now, 6 under way, 2 of them phase 3. Rhinosinusitis · France.

Started
2022
the only one that year
Observational
6 of 14
2 open now
Registered
5th of 14
by date
Lead sponsor
1 of 14
Lallemand Pharma AG

Among the 14 studies in Rhinosinusitis with a site in France, this one is the only one that started in 2022, is one of 6 observational ones, and was the 5th registered.

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

4 of the 14 studies in Rhinosinusitis with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Rhinosinusitis with a site in France, or all of them as a file.
02

Study summary

Healsea® chronic is CE marked medical device indicated in adults for the treatment of nasal symptoms of chronic rhinosinusitis. This is an hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract (0.2%) isolated from marine bacteria. In vitro, Symbiofilm® inhibits at early stage biofilm formation from bacteria found to be more prevalent and abundant in CRS patients (e.g. Staphylococcus aureus, Pseudomonas aeruginosa). This exploratory study is designed with aim to determine if the antibiofilm properties of Symbiofilm® may modify sino-nasal microbiota, impacting α and/ or β diversities.

Read the detailed description

Chronic rhinosinusitis (CRS) is an inflammation of the nose and paranasal sinuses and is characterized by two or more symptoms, one of which should be either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip), lasting for 12 weeks or longer. In addition, facial pain or pressure and a reduction in the sense of smell can occur. The condition can occur with or without nasal polyps.

Chronic rhinosinusitis (CRS) is a significant health problem and affects 5-12% of the general population.

The physiopathology of CRS is poorly understood with multiple environmental, host and microbial factors being implicated. Putative pathological factors include changes in the microbiota, imbalance of the local or systemic immune system, allergens, toxins and genetic predisposition.

A dysbiosis mechanism has been proposed as modulating inflammation in diseased sinuses. This hypothesis suggests that externally influenced changes in the nasal microbiome can result in dysbiosis, i.e. a shift from a "normal" or "healthy" microbial community structure and that this shift may be responsible for the initiation or maintenance of CRS. For example, the disruption of the commensal biofilm during a viral upper respiratory tract infection can create a niche for pathogenic species to grow. Despite many contradictory statements in the different studies some common trends emerge. Less diversity in the microbial community rather than an increased overall bacterial load seems to characterize CRS compared to the healthy state with no consensus about specific genera indicative of disease. However, anaerobes and S. aureus are found to be significantly more prevalent and abundant in CRS versus healthy controls. Bacterial biofilm is detected on the sinus mucosa in up to 80% of CRS patients and its presence does not imply that it is causing mucosal inflammation. However, in the context of CRS, there are several possible mechanisms by which biofilms may be pro-inflammatory including the release of planktonic organisms and the release of superantigens, which can cause ciliary dysfunction and inhibition of ciliary clearance. Bacterial biofilms are likely a key modulator of the refractory nature of CRS.

Although clinical evidence from well-designed trials is scarce, European Guidelines for chronic rhinosinusitis recommend daily nasal saline irrigation for reduction of the severity of symptoms of CRS. A recent Cochrane analysis has concluded that daily nasal irrigation with hypertonic saline solution is more effective than placebo to improve patient symptoms. The exact mechanisms by which nasal irrigation works are not known. However, most of the experts agree that it is primarily a mechanical intervention leading to direct cleansing of the nasal mucosa. Nevertheless, the efficacy of such solution remains moderate.

Healsea® Chronic is a CE marked medical device indicated in adults for the treatment of nasal symptoms of chronic rhinosinusitis. This is a seawater-based nasal spray supplemented with a natural Symbiofilm® extract (0.02%) isolated from marine bacteria. The nasal solution is hypertonic (NaCl 2.2%). Symbiofilm® is a marine postbiotic comprising active exopolysaccharides with emulsifying properties and in vitro antibiofilm activity. Antibiofilm properties have been demonstrated with the colorimetric microtiter plate assay. In this model, a significant inhibition of biofilm formation by Staphylococcus aureus and Haemophilus influenzae are observed. Detachment properties from human nasal epithelial cells of Staphylococcus aureus and Pseudomonas aeruginosa has also been demonstrated in vitro, suggesting an inhibition of biofilm formation at early stage in this model. Symbiofilm® has no bacteriostatic nor bactericidal activities.

To date, properly designed studies to evaluate the effect of topical therapies on microbiome are scarce so no definite conclusion can be made. In one study, use of saline irrigation with or without budesonideDCI used was not associated with significantly distinct microbiota composition among either controls or post-operative CRS patients with polyp.

This exploratory study is designed with aim to determine if the antibiofilm properties of Symbiofilm® may modify sino-nasal microbiota, impacting α and/ or β diversities. To this end middle meatus swab specimen will be taken from CRS patients before and after treatment with Healsea® Chronic. Bacteria colonization will be assessed using quantitative PCR and 16S rRNA gene sequencing.

Improvement of nasal symptoms and quality of life will be assessed with the Sino-Nasal Outcome Test score-22 (SNOT-22). Post-market vigilance of Healsea® Chronic and vigilance of study procedures will be assessed throughout the study.

03

Conditions studied

  • Rhinosinusitis Chronic
  • Microbiome

Browse trials for

Keywords

  • Rhinosinusitis chronic
  • Adult
  • Biofilm
  • 16S rRNA sequencing
  • Nasal spray
  • Microbiome
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The subjects will be recruited by the site among outpatients coming for routine consultation because of CRS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 - 70 years
  2. Provision of signed and dated form
  3. Stated willingness to comply with all study procedures and availability for the duration of the study
  4. Diagnosed with CRS based on the diagnostic criteria of the EPOS guideline
  5. Registered with a social security scheme or covered by such a regime

Exclusion criteria

Exclusion Criteria:

  1. Antibiotics or oral intake in the month prior to the study
  2. Endoscopic sinus surgery in the past 6 months
  3. Cystic fibrosis
  4. Wegener's granulomatosis
  5. Immunodeficiency
  6. Defective access to middle meatus
  7. Lidocaine allergy
  8. Known /allergy to any component of the test device
  9. Pregnant/Lactating female or absence of efficient
  10. Under tutorship or guardianship
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
12 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Test Medical Device

    Healsea Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days

    Device: Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract

Interventions

  • DeviceHealsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract

    Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days

06

What researchers measure

Primary outcomes

  1. Comparaison of Alpha-diversity of Sino-nasal Microbiota Before and After Treatment (Visit 1 and Visit 2)

    Comparaison of the values of alpha diversity of bacterial species assessed by the Shannon index at baseline and after the treatment period

    Time frame: At baseline (V1) and at end of the 30-day treatment period (V2)

Secondary outcomes

  1. Impact of Healsea® Chronic on Quality of Life Assessed by the Sino-Nasal Outcome Test Score-22

    Change of SNOT-22 total score at the end of the 30-day treatment period versus baseline . A change \>-9 is deemed clinically meaningful.

    Time frame: End of treatment (Visit 2(V2)-Day 30) versus screening/inclusion (Visit 1(V1)-Day 1)

  2. Patient Satisfaction Questionnaire (Usability)

    To assess patient 's satisfaction regarding the medical device usability

    Time frame: Visit 2(V2)-Day 30 (end of treatment)

  3. Patient Satisfaction Questionnaire (Taste)

    To assess patient 's satisfaction regarding the sensory perception (residual taste after spraying)

    Time frame: Visit 2(V2)-Day 30 (end of treatment)

  4. Patient Satisfaction Questionnaire (Efficacy)

    To assess patient 's satisfaction regarding product efficacy for chronic Rhinosinusitis (Cleansing and Moistening of nasal mucosa)

    Time frame: Visit 2(V2)-Day 30 (end of treatment)

Other outcomes

  1. Reporting of Adverse Events, Incidents and Expected Side Effects

    Assessment of materiovigilance from the medical device (incidents, expected side effects) and reporting of adverse reactions related to the additional invasive procedure (swab of the nasal meatus)

    Time frame: During the intervention, up to 30 days

07

Results

Posted Nov 8, 2024
Limitations and caveats
Small number of subjects (12 VS 20 expected)

Participant flow

The subjects will be recruited by the site among outpatients coming for routine consultation because of CRS. The first patient was screened and enrolled on 12th December 2022, the last patient was screened and enrolled on 25th April 2023.

Participant flow — Overall Study
MilestoneHealsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Started12
Safety set12
Full analysis set (fas)12
Per protocol set (pp)3
Completed12
Not completed0

Outcome measures

PrimaryComparaison of Alpha-diversity of Sino-nasal Microbiota Before and After Treatment (Visit 1 and Visit 2)

Comparaison of the values of alpha diversity of bacterial species assessed by the Shannon index at baseline and after the treatment period

Time frame:
At baseline (V1) and at end of the 30-day treatment period (V2)
Reported as:
Mean · Shannon Index
Comparaison of Alpha-diversity of Sino-nasal Microbiota Before and After Treatment (Visit 1 and Visit 2)
Shannon IndexHealsea® Chronic Baseline ValueHealsea® Chronic After 30-day Treatment
Comparaison of Alpha-diversity of Sino-nasal Microbiota Before and After Treatment (Visit 1 and Visit 2)2.041 ± 0.9002.114 ± 1.041
Statistical analysis
  • Healsea® Chronic Baseline Value vs Healsea® Chronic After 30-day Treatment · Kruskal-Wallis · p = 0.908
SecondaryImpact of Healsea® Chronic on Quality of Life Assessed by the Sino-Nasal Outcome Test Score-22

Change of SNOT-22 total score at the end of the 30-day treatment period versus baseline . A change \>-9 is deemed clinically meaningful.

Time frame:
End of treatment (Visit 2(V2)-Day 30) versus screening/inclusion (Visit 1(V1)-Day 1)
Reported as:
Mean · score on a scale
Impact of Healsea® Chronic on Quality of Life Assessed by the Sino-Nasal Outcome Test Score-22
score on a scaleHealsea Chronic Nasal Spray Baseline ValueHealsea® Chronic Nasal Spray After 30 Days
Absolute values of SNOT-22 total score59.3 ± 21.241.8 ± 25.5
Change of SNOT-22 total score versus baseline0 ± 0-17.5 ± 17
SecondaryPatient Satisfaction Questionnaire (Usability)

To assess patient 's satisfaction regarding the medical device usability

Time frame:
Visit 2(V2)-Day 30 (end of treatment)
Reported as:
Count of participants · Participants
Patient Satisfaction Questionnaire (Usability)
ParticipantsHealsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Missing0
Not easy0
Pretty easy0
Easy0
Very easy12
SecondaryPatient Satisfaction Questionnaire (Taste)

To assess patient 's satisfaction regarding the sensory perception (residual taste after spraying)

Time frame:
Visit 2(V2)-Day 30 (end of treatment)
Reported as:
Count of participants · Participants
Patient Satisfaction Questionnaire (Taste)
ParticipantsHealsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Missing0
Not pleasant0
Neutral8
Pleasant3
Very pleasant1
SecondaryPatient Satisfaction Questionnaire (Efficacy)

To assess patient 's satisfaction regarding product efficacy for chronic Rhinosinusitis (Cleansing and Moistening of nasal mucosa)

Time frame:
Visit 2(V2)-Day 30 (end of treatment)
Reported as:
Count of participants · Participants
Patient Satisfaction Questionnaire (Efficacy)
ParticipantsHealsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Missing0
No improvement0
Slight improvement2
Moderate improvement6
Very clear improvement4
Other pre-specifiedReporting of Adverse Events, Incidents and Expected Side Effects

Assessment of materiovigilance from the medical device (incidents, expected side effects) and reporting of adverse reactions related to the additional invasive procedure (swab of the nasal meatus)

Time frame:
During the intervention, up to 30 days

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events/incidents were collected during the intervention and up to 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract0/12 (0%)0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventHealsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/12
Mouth ulcerationGastrointestinal disorders1/12
Palatal disorderGastrointestinal disorders1/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
<=18 years0
Between 18 and 65 years10
>=65 years2
Age, Continuous
Age, Continuous(years)Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Mean43.5 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Female11
Male1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported12
Region of Enrollment
Region of Enrollment(participants)Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
France12
Baseline SNOT-22 (total)
Baseline SNOT-22 (total)(score on a scale)Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Mean59.3 ± 21.2
α diversity
α diversity(Shannon Index)Healsea® Chronic: Hypertonic Seawater-Based Nasal Spray With Natural Symbiofilm® Extract
Mean2.041 ± 0.900
08

Study locations

1 site
  • Larrey Hospital
    Toulouse, 31400, France
09

References and documents

Publications

  • Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O'Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Sindvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600. PubMed 32077450 ↗
  • Sivasubramaniam R, Douglas R. The microbiome and chronic rhinosinusitis. World J Otorhinolaryngol Head Neck Surg. 2018 Oct 31;4(3):216-221. doi: 10.1016/j.wjorl.2018.08.004. eCollection 2018 Sep. PubMed 30506054 ↗
  • Boase S, Foreman A, Cleland E, Tan L, Melton-Kreft R, Pant H, Hu FZ, Ehrlich GD, Wormald PJ. The microbiome of chronic rhinosinusitis: culture, molecular diagnostics and biofilm detection. BMC Infect Dis. 2013 May 8;13:210. doi: 10.1186/1471-2334-13-210. PubMed 23656607 ↗
  • Ramakrishnan VR, Hauser LJ, Frank DN. The sinonasal bacterial microbiome in health and disease. Curr Opin Otolaryngol Head Neck Surg. 2016 Feb;24(1):20-5. doi: 10.1097/MOO.0000000000000221. PubMed 26575518 ↗
  • Hoggard M, Wagner Mackenzie B, Jain R, Taylor MW, Biswas K, Douglas RG. Chronic Rhinosinusitis and the Evolving Understanding of Microbial Ecology in Chronic Inflammatory Mucosal Disease. Clin Microbiol Rev. 2017 Jan;30(1):321-348. doi: 10.1128/CMR.00060-16. PubMed 27903594 ↗
  • Koeller K, Herlemann DPR, Schuldt T, Ovari A, Guder E, Podbielski A, Kreikemeyer B, Olzowy B. Microbiome and Culture Based Analysis of Chronic Rhinosinusitis Compared to Healthy Sinus Mucosa. Front Microbiol. 2018 Apr 17;9:643. doi: 10.3389/fmicb.2018.00643. eCollection 2018. PubMed 29755418 ↗
  • Fastenberg JH, Hsueh WD, Mustafa A, Akbar NA, Abuzeid WM. Biofilms in chronic rhinosinusitis: Pathophysiology and therapeutic strategies. World J Otorhinolaryngol Head Neck Surg. 2016 May 5;2(4):219-229. doi: 10.1016/j.wjorl.2016.03.002. eCollection 2016 Dec. PubMed 29204570 ↗
  • Chong LY, Head K, Hopkins C, Philpott C, Glew S, Scadding G, Burton MJ, Schilder AG. Saline irrigation for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011995. doi: 10.1002/14651858.CD011995.pub2. PubMed 27115216 ↗
  • O'Toole GA. Microtiter dish biofilm formation assay. J Vis Exp. 2011 Jan 30;(47):2437. doi: 10.3791/2437. PubMed 21307833 ↗
  • Liu CM, Kohanski MA, Mendiola M, Soldanova K, Dwan MG, Lester R, Nordstrom L, Price LB, Lane AP. Impact of saline irrigation and topical corticosteroids on the postsurgical sinonasal microbiota. Int Forum Allergy Rhinol. 2015 Mar;5(3):185-90. doi: 10.1002/alr.21467. Epub 2014 Dec 29. PubMed 25556553 ↗
  • Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009 Oct;34(5):447-54. doi: 10.1111/j.1749-4486.2009.01995.x. PubMed 19793277 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in May 2023, 5 months.

Results were first posted in Nov 2024, 1 year 5 months after primary completion.

Of 22 observational studies under Rhinosinusitis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 71. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2021
First posted
Aug 20, 2021
StartActual
Dec 12, 2022
Primary completionActual
May 19, 2023
CompletionActual
May 19, 2023
Results first posted
Nov 8, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05015530
Lead sponsor
Lallemand Pharma AG
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Dec 12, 2022
Primary completion
May 19, 2023
Completion
May 19, 2023
Results posted
Nov 8, 2024
Last update
Nov 8, 2024

Study contacts

Pr Guillaume de Bonnecaze, MD, PhD
principal investigator · Department of Otorhinolaryngology , University Hospital of Toulouse (Larrey), France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion